DE3688900D1 - Expression von protein c. - Google Patents

Expression von protein c.

Info

Publication number
DE3688900D1
DE3688900D1 DE8686304970T DE3688900T DE3688900D1 DE 3688900 D1 DE3688900 D1 DE 3688900D1 DE 8686304970 T DE8686304970 T DE 8686304970T DE 3688900 T DE3688900 T DE 3688900T DE 3688900 D1 DE3688900 D1 DE 3688900D1
Authority
DE
Germany
Prior art keywords
protein
nucleotide sequence
disclosed
mammalian host
biological activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686304970T
Other languages
English (en)
Other versions
DE3688900T2 (de
DE3688900T3 (de
Inventor
Mark J Murray
Kathleen L Berkner
Donald C Foster
Earl W Davie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Zymogenetics Inc
Original Assignee
University of Washington
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27115147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3688900(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/766,109 external-priority patent/US4968626A/en
Application filed by University of Washington, Zymogenetics Inc filed Critical University of Washington
Publication of DE3688900D1 publication Critical patent/DE3688900D1/de
Publication of DE3688900T2 publication Critical patent/DE3688900T2/de
Application granted granted Critical
Publication of DE3688900T3 publication Critical patent/DE3688900T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE3688900T 1985-06-27 1986-06-26 Expression von Protein C. Expired - Lifetime DE3688900T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74960085A 1985-06-27 1985-06-27
US06/766,109 US4968626A (en) 1985-08-15 1985-08-15 DNA sequence coding for protein C

Publications (3)

Publication Number Publication Date
DE3688900D1 true DE3688900D1 (de) 1993-09-23
DE3688900T2 DE3688900T2 (de) 1993-12-09
DE3688900T3 DE3688900T3 (de) 1998-06-10

Family

ID=27115147

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3688900T Expired - Lifetime DE3688900T3 (de) 1985-06-27 1986-06-26 Expression von Protein C.

Country Status (7)

Country Link
EP (1) EP0215548B2 (de)
JP (2) JP2614848B2 (de)
AT (1) ATE93272T1 (de)
CA (1) CA1341228C (de)
DE (1) DE3688900T3 (de)
DK (1) DK175574B1 (de)
NO (1) NO305660B1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5550036A (en) * 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
USH1148H (en) 1987-04-17 1993-03-02 Method of separating activated human protein C
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
ES2047946T3 (es) * 1989-08-11 1994-03-01 Zymogenetics Inc Metodos de cultivos celulares para producir proteina c activada.
JP2774156B2 (ja) * 1989-09-05 1998-07-09 帝人株式会社 ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
JP2774163B2 (ja) * 1989-11-14 1998-07-09 帝人株式会社 ヒトプロテインｃ様活性を有する蛋白
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
WO1991009960A1 (en) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Hybrid protein c
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
JPH08508875A (ja) * 1992-05-01 1996-09-24 帝人株式会社 蛋白分泌細胞の流加回分培養法
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
WO2001036462A2 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
MX2007014674A (es) * 2005-05-24 2008-03-07 Avestha Gengraine Tech Pvt Ltd Proceso que comprende la optimizacion del codon para la produccion de la proteina c humana, activada, recombinante para el tratamiento de sepsis.
BR112015008754A2 (pt) 2012-10-23 2017-07-04 Koninklijke Philips Nv sistema de medição de estresse para determinar um nível de estresse de um usuário

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C

Also Published As

Publication number Publication date
EP0215548B1 (de) 1993-08-18
DE3688900T2 (de) 1993-12-09
DE3688900T3 (de) 1998-06-10
EP0215548A1 (de) 1987-03-25
NO305660B1 (no) 1999-07-05
JPS62111690A (ja) 1987-05-22
JP2688407B2 (ja) 1997-12-10
CA1341228C (en) 2001-05-15
DK308586A (da) 1986-12-28
NO862601L (no) 1986-12-29
JP2614848B2 (ja) 1997-05-28
ATE93272T1 (de) 1993-09-15
DK308586D0 (da) 1986-06-27
EP0215548B2 (de) 1998-01-07
NO862601D0 (no) 1986-06-27
DK175574B1 (da) 2004-12-13
JPH09107976A (ja) 1997-04-28

Similar Documents

Publication Publication Date Title
NO874495L (no) Ekspresjon av protein c.
ATE93272T1 (de) Expression von protein c.
ATE391175T1 (de) Multidrug resistenz gen
FI963246A (fi) Geeniterapiassa käytettävä isäntävektorijärjestelmä
ATE88501T1 (de) Rekombinante dns-expressionsvektoren.
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
PT82408A (en) Expression of factor vii and ix activities in mammalian cells
EP0232112A3 (en) Recombinant protein complex having human factor viii:c activity its production and use
DK127786D0 (da) Fremgangsmaade til fremstilling af tgf-beta, dna og mrna, som koder for tgf-beta, samt replicerbare vektorer omfattende dna'en og vaertscellerindeholdende vektorerne
EP0111814A3 (de) Klonierung und Expression von nucleotiden Sequenzen die für Rinderwachstumshormon kodieren
ES2078243T3 (es) Mejoras en o relativas a la expresion eucariotica.
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
ATE181115T1 (de) Stabilisierung von messenger-rns in tierischen zellen
ATA435083A (de) Das polypeptid interleukin-2 kodierendes gen, rekombinante, dieses gen enthaltende dna, diese rekombinante dna aufweisende zellinien und verfahren zur herstellung von interleukin-2 unter verwendung der genannten zellen
ATE111527T1 (de) Herstellung und verwendung einer dna zur erhöhung der ausbeute bei der expression von rekombinanten genen.
WO1991009951A3 (en) Recombinant protein c with truncated light chain
ES2005189A6 (en) Nucleotide sequences from RESA antigen of Plasmodium falciparum
NO179453C (no) Fremgangsmåte for fremstilling av terapeutisk aktivt amphiregulin, vertscelle som produserer proteinet, rekombinant vektor inneholdt i vertscellen, samt nukleotidsekvens som koder for proteiner med amphiregulinaktivitet

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings